Dr. Frederick Greene, our Consulting Medical Officer has leveraged his extensive surgical experience and his ongoing editorial experiences with the AJCC and CoC to drive several initiatives for CRStar - including the industry's first podcast focused on Cancer Registry.
Predicting Cancer Recurrence One of the most frequent questions from patients is whether their cancer will come back after their surgical, radiation, or chemotherapy treatment is complete. Analyses of circulating tumor cells or the DNA associated with those cells (ctDNA) may be the answers. Can postoperative circulating tumor DNA (ctDNA) status predict recurrence-free survival (RFS) […]
The Disruption and Recovery of Cancer Diagnoses Following COVID-19 As we begin 2025, discussions of flu-like illnesses are extremely relevant, especially ongoing issues related to the COVID-19 pandemic. A critical question to consider is: to what extent was cancer detection in the U.S. disrupted during the pandemic's first year, and how much progress was made […]
The Benefits of a "Complete Response" For many cancer sites, the use of neoadjuvant radiation and/or chemotherapy is becoming a standard strategy. One of the greatest benefits is the opportunity to achieve a complete clinical or pathological response prior to surgical resection. In the management of pancreatic adenocarcinoma, achieving a pathologic complete response was associated […]
The De-escalation of Breast Cancer Therapy One of the great challenges in modern cancer management is to limit or discontinue traditional therapies that have not proven beneficial in certain populations of patients. Adjuvant radiotherapy is prescribed after breast-conserving surgery to reduce the risk of local recurrence. However, radiotherapy is inconvenient, costly, and associated with both […]
Male Breast Cancer Despite the overwhelming number of breast cancer cases in women, the importance of male breast cancer collected by our cancer registries remains an important topic. One important question would be: What is the breast cancer–specific mortality (BCSM) risk over 20 years in men with stage I to III hormone receptor–positive breast cancer? In […]
